Belite Bio (NASDAQ:BLTE) Shares Climb 7.1% on Earnings Beat

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE – Get Free Report) rose 7.1% during mid-day trading on Thursday following a better than expected earnings announcement. The company traded as high as $163.00 and last traded at $167.0560. 117,062 shares changed hands during trading, a decline of 38% from the average session volume of 188,958 shares. The stock had previously closed at $155.94.

The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.19.

Latest Belite Bio News

Investors following BLTE have been watching these news items:

  • Positive Sentiment: Leerink Partners raised its price target to $215 from $185 and reiterated an “outperform” rating, signaling confidence in Belite Bio’s outlook. TickerReport article
  • Positive Sentiment: Belite reported a third-quarter loss of $0.60 per share, narrower than analysts’ expected loss of $0.79, providing a modest earnings beat. Quarterly earnings results
  • Negative Sentiment: The company recorded a $30.3 million quarterly net loss, underscoring the costs and risks of developing its drug candidate before potential commercialization. Quarterly loss report

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on BLTE shares. Mizuho increased their price objective on shares of Belite Bio from $220.00 to $234.00 and gave the company an “outperform” rating in a research note on Wednesday, September 9th. Leerink Partners boosted their price objective on shares of Belite Bio from $185.00 to $215.00 and gave the stock an “outperform” rating in a research note on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Belite Bio in a research note on Friday, October 2nd. Benchmark restated a “buy” rating on shares of Belite Bio in a report on Friday, August 14th. Finally, Cantor Fitzgerald upped their target price on Belite Bio from $266.00 to $270.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Nine investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $226.27.

View Our Latest Stock Report on Belite Bio

Insider Buying and Selling at Belite Bio

In other Belite Bio news, CEO Yu-Hsin Lin sold 74,435 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $187.71, for a total value of $13,972,193.85. Following the completion of the transaction, the chief executive officer directly owned 96,134 shares in the company, valued at approximately $18,045,313.14. The trade was a 43.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Hendrik Scholl sold 500 shares of the stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $165.32, for a total transaction of $82,660.00. Following the sale, the insider directly owned 14,500 shares of the company’s stock, valued at approximately $2,397,140. The trade was a 3.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 168,330 shares of company stock worth $31,969,118 over the last quarter. Insiders own 13.29% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Marshall Wace LLP bought a new position in shares of Belite Bio during the 3rd quarter worth approximately $15,282,000. State Street Corp boosted its stake in Belite Bio by 6.9% in the third quarter. State Street Corp now owns 34,044 shares of the company’s stock valued at $5,781,000 after acquiring an additional 2,196 shares in the last quarter. Alberta Investment Management Corp acquired a new stake in Belite Bio in the third quarter valued at approximately $4,076,000. Candriam S.C.A. acquired a new stake in Belite Bio in the third quarter valued at approximately $10,711,000. Finally, Vise Technologies Inc. acquired a new stake in Belite Bio in the third quarter valued at approximately $217,000. Hedge funds and other institutional investors own 0.53% of the company’s stock.

Belite Bio Price Performance

The company’s fifty day simple moving average is $160.88 and its 200-day simple moving average is $160.24. The firm has a market capitalization of $6.62 billion, a PE ratio of -60.20 and a beta of -1.19.

Belite Bio Company Profile

(Get Free Report)

Belite Bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for retinal and metabolic diseases. The company focuses on conditions with limited treatment options, including inherited retinal disorders and age-related eye disease. Its lead drug candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of toxic vitamin A byproducts in the retina. Belite Bio is evaluating tinlarebant for Stargardt disease and geographic atrophy associated with dry age-related macular degeneration.

Featured Articles

Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.